Zenkuda achieved comparable visual and anatomical outcomes in all RVO patients, irrespective of the treatment paradigm used Mean observed data; Week 24 and 48 datapoints are Mean (Standard Deviation). Results for BCVA are based on a mixed model repeated measures (MMRM) analysis, with the change from baseline value as the dependent variable; treatment, visit (Week 1 through Week 48), and treatment by visit interaction as fixed effects; randomization stratification variables [baseline BCVA, disease duration, RVO type) and geographical location], as well as continuous covariates of baseline BCVA value and baseline OCT CMM value, as fixed effects; and subject as a random effect. a. Nominal p-value. Non-inferiority margin = 4.5 ETDRS letters. With two fewer doses (4 vs 6), similar visual and anatomical gains Zenkuda Aflibercept LSM change from BL BCVA at Week 48 (MMRM 11.7 12.8 95% CI for LSM difference -3.11, 0.94 P-value for non- inferiority a p = 0.001 75% achieved 6-month durability, similar visual and anatomical gains Fixed Dosing (0-24) Doubling of treatment interval Head-to-head Individualized Dosing (24-48) Zenkuda vs aflibercept Mean BCVA over time Mean CST over time 25